Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company based in Foster City, California, known for discovering, developing and commercializing innovative medicines that address serious unmet medical needs in areas such as HIV/AIDS, viral hepatitis, COVID-19, oncology and inflammation. Gilead Sciences has a market capitalization of around $155 billion, reflecting its position as a major player in the healthcare and biotechnology sectors.
The company will soon announce its fiscal fourth quarter earnings results. Ahead of the event, analysts expect GILD to post earnings of $1.86 per share, down 2.1% from $1.90 per share in the year-ago quarter. The company beat Wall Street earnings estimates in three of the last four quarters and missed them on another occasion.
For fiscal 2025, analysts expect GILD to post EPS of $8.14, up 76.2% from $4.62 in fiscal 2024. Additionally, its EPS is expected to rise 4.8% in fiscal 2026 to $8.53.
GILD has risen 36.3% over the past year, outperforming the S&P 500 ($SPX)’s 16.9% gains and the State Street Health Care Select Sector SPDR ETF’s (XLV) 10.4% return over the same time period.
Gilead shares have been rising as investors are encouraged by new product approvals and pipeline progress, particularly momentum in HIV prevention drug Yeztugo and strong performance of the HIV franchise. The FDA approval and commercial launch of the new HIV prevention product, the twice-yearly injectable Yeztugo, will expand the company’s potential market and increase investor confidence.
The consensus view on GILD is bullish, with an overall rating of “Strong Buy.” Among the 30 analysts covering the stock, 22 recommend a “strong buy,” two recommend a “moderate buy” and six suggest a “hold.” The average price target of GILD analysts is $135.67, indicating a potential upside of 8.6% from current price levels.
On the date of publication, Subhasree Kar had no positions (either directly or indirectly) in any of the securities mentioned in this article. All information and data in this article are for informational purposes only. This article was originally published on Barchart.com